eriseld krasniqi

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Cancer Biology Cancer Biology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (12)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Nicola Tinari

University of Chieti-Pescara

ITALY

View details

Aldo Venuti

Prof

Istituto Regina Elena

ITALY

View details

francesca sperati

Istituto San Gallicano

ITALY

View details

Paolo Marchetti

Sapienza University of Rome

ITALY

View details

Francesco Pantano

National Academic Qualification as Full Professor (Abilitazione Scientifica Nazionale a Professore di I Fascia) in Hematology, Oncology and Rheumatology (MED 06/D3)

Ministero dell’Istruzione, dell’Università e della Ricerca

ITALY

View details

Nicla La Verde

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

eriseld krasniqi

Research Interests

Explore related searches

Contact this professor

Articles (12)

DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos Study

HER2 mutation as an emerging target in advanced breast cancer

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration

KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub

The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience

Burnout of health care providers during the covid-19 pandemic: Focus on medical oncologists

Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives

Circulating hpv dna in the management of oropharyngeal and cervical cancers: Current knowledge and future perspectives

Collaborators (6)

Nicola Tinari

Aldo Venuti

francesca sperati

Paolo Marchetti

Francesco Pantano

Nicla La Verde

Make your next move.